Wenzhou Kangning Hospital Co (HKSE:02120) Research & Development: HK$34 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02120 Wenzhou Kangning Hospital Co Ltd HKSE:02120
75 GF Score
Price HK$9.26
GF Value HK$13.13
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Wenzhou Kangning Hospital Co Research & Development?

Wenzhou Kangning Hospital Co HKSE:02120 +2.15% 75 Research & Development is HK$34 Mil as of Jun. 2026. GuruFocus rates HKSE:02120 with a GF Score™ of 75/100 and a GF Value™ of HK$13.13 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Wenzhou Kangning Hospital Co's Research & Development for the six months ended in Jun. 2026 was HK$18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was HK$34 Mil.

Wenzhou Kangning Hospital Co  (HKSE:02120) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Wenzhou Kangning Hospital Co Research & Development Related Terms

Wenzhou Kangning Hospital Co Research & Development Historical Data

* Premium members only.

The historical data trend for Wenzhou Kangning Hospital Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wenzhou Kangning Hospital Co Research & Development Chart

Wenzhou Kangning Hospital Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.24 36.88 35.51 38.99 33.28

Wenzhou Kangning Hospital Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.93 20.21 17.12 15.98 18.06
HKSE:02120
75GF Score
Wenzhou Kangning Hospital Co Ltd HKSE:02120
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wenzhou Kangning Hospital Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$34 Mil mean?
Wenzhou Kangning Hospital Co (HKSE:02120) has a Research & Development of HK$34 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Wenzhou Kangning Hospital Co and its competitors.
Is Wenzhou Kangning Hospital Co's Research & Development too high?
Wenzhou Kangning Hospital Co's current Research & Development is HK$34 Mil. Overall, Wenzhou Kangning Hospital Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wenzhou Kangning Hospital Co's Research & Development compare to HCA and THC?
Wenzhou Kangning Hospital Co's Research & Development of HK$34 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Wenzhou Kangning Hospital Co and its competitors. Wenzhou Kangning Hospital Co's current Research & Development is HK$34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wenzhou Kangning Hospital Co stock overvalued right now?
Based on GuruFocus' analysis, Wenzhou Kangning Hospital Co (HKSE:02120) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.13, compared to a current price of HK$9.26 — trading 29.5% below its estimated fair value. The current Research & Development is HK$34 Mil. Wenzhou Kangning Hospital Co's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Wenzhou Kangning Hospital Co (HKSE:02120), the current Research & Development is HK$34 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wenzhou Kangning Hospital Co (HKSE:02120) Overvalued in 2026?

Based on GuruFocus' analysis, Wenzhou Kangning Hospital Co stock appears to be undervalued. The current stock price of HK$9.26 is trading 29.5% below its estimated GF Value™ of HK$13.13. GuruFocus considers Wenzhou Kangning Hospital Co to be Modestly Undervalued.

Key valuation signals for HKSE:02120:

  • Research & Development: HK$34 Mil
  • GF Value™: HK$13.13 vs. price of HK$9.26 (29.5% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the HKSE:02120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wenzhou Kangning Hospital Co Business Description

Address No.1 Shengjin Road, Huanglong Residential District, Zhejiang, Wenzhou, CHN
Wenzhou Kangning Hospital Co Ltd is engaged in operating a network of healthcare facilities that focus on providing psychiatric specialty care and elderly rehabilitation service across various regions in China. It derives revenue from operating its owned hospitals consists of fees charged for outpatient visits and inpatient services at the group's various hospitals, which can be divided into treatment and general healthcare services and pharmaceutical sales, as well as variable considerations for medical services provided by the group, mainly including medical insurance settlement differences.
75GF Score

Get the complete analysis for HKSE:02120

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$9.26
Price
HK$13.13
GF Value